Mesenchymal stem cell‑derived extracellular vesicles prevent neural stem cell hypoxia injury via promoting miR‑210‑3p expression

Introduction

Neural stem cells (NSCs) are able to self-renew and differentiate into neurons, oligodendrocytes and astrocytes under appropriate inducing conditions (1); therefore, NSCs are the most commonly used stem cells in repairing neuronal injuries (2). In neurogenesis, NSCs exist in the developing brain and serve an important role in brain plasticity throughout life (3,4). Transplanting NSCs into the host brain is an efficient strategy to repair neuronal injury and treat neurodegenerative diseases (5).

Mesenchymal stem cells (MSCs) have the potential of multidirectional differentiation and neuroprotective effects (6). Notably, it may be the secretory products rather than the stem cells themselves, which serve a dominant role in neuroprotection (7–10). Extracellular vesicles (EVs) of MSCs have advantages, including being more efficient when used in the treatment of diseases compared with MSCs (11–13). EVs carry a variety of proteins, lipids, RNAs, microRNAs (miRs) and other molecules, and have a high ability to enter into target cells (14,15). Among the cargo of EVs, miRs are critical posttranscriptional factors that regulate biological and physiological functions (16). A large number of different miRs are expressed sequentially and participate in the process of nerve repair or promote neuron regeneration following peripheral nerve injury (17). miR-210-3p is a key regulator that determines neuron survival under hypoxic conditions (18). miR-210-3p inhibits apoptosis and promotes cell survival under oxygen-glucose deprivation and oxidative stress conditions, and repairs neurons following spinal cord injury (19). In addition, miR-210-3p is present in EVs, which indicates a possible physiological function for miR-210-3p (20).

Cobalt chloride is widely used to produce in vitro hypoxic injury models in NSCs (21,22) as it triggers NSC apoptosis via the nuclear factor erythroid 2-related factor 2 (Nrf2)/antioxidant response elements (ARE) signaling pathway (21). The present study aimed to examine the potential function of miR-210-3p in the protective effects of MSC-EVs against NSC hypoxic injury regarding NSC apoptosis.

Materials and methods

Animals

A total of 5 pregnant Sprague-Dawley (SD) rats (350 g, aged 3 months) were purchased from Hunan Slake Jingda Laboratory Animal Co., Ltd. (license no. SCXK (Hunan) 2016-0002). The animals were housed in a specific pathogen-free environment at 23±2°C with 45–65% humidity, 12-h light/dark cycles and free access to food and water. All experimental protocols were approved by the Ethics Committee of Kunming Medical University.

Preparation of EVs from MSCs

MSCs were purchased from BeNa Culture Collection (cat no. BNCC 340370; Suzhou Bena Chuanglian Biotechnology Co. Ltd.). After 48-h starvation using fetal bovine serum (FBS)-free Cellartis MSC Xeno-Free Culture Medium (cat. no. Y50200, Cellartis; Takara Bio Europe AB), EVs were prepared using an Exosome Extraction kit (cat no. E1310, Beijing Weihui Biotechnology Co., Ltd.) following the manufacturer's protocol. Cells and cell debris were removed by centrifugation at 2,000 × g at 4°C for 10 min. Subsequently, the EVs were fixed in 2.5% glutaraldehyde for 2 h at room temperature. Following embedding in epoxy-based resins at room temperature for 3 h, the samples were sectioned into 70-nm slices and stained with 3% uranium acetate and 3% lead citrate at room temperature for 5 min. The slides were observed via transmission electron microscopy (JEM-1230; JEOL, Ltd.) at 80KV. The particle sizes of exosomes were measured using a Laser Particle Size Analyzer (LA-960; HORIBA Scientific).

Preparation of NSCs

A total of 5 pregnant rats (age, 15 days; weight, 300 g) were anesthetized with isoflurane (5%) and then decapitated. The fetal rats were sterilized with 75% ethanol for 30 min at room temperature. The hippocampus tissue was separated and immersed in Hanks' Balanced Salt solution (Thermo Fisher Scientific, Inc.). After being fully shredded, the hippocampus tissue was digested with 0.125% trypsin for 10 min and the reaction was terminated using Dulbecco's Minimum Essential Medium (Gibco; Thermo Fisher Scientific, Inc.). The cells were collected and suspended in fresh medium containing 10% FBS (Hyclone; Cytivia) and cultured in a 5% CO2 incubator at 37°C.

Immunohistochemistry

The collected cells were fixed in 4% paraformaldehyde for 30 min at room temperature. Endogenous peroxidase activity was blocked with 3% (v/v) H2O2 for 5 min at room temperature. The slides were blocked in 5% bovine serum albumin (Hyclone, Thermo Fisher Scientific, Inc.) at room temperature for 2 h and incubated with a monoclonal anti-nestin primary antibody (1:200; cat no. OM264981; Omnimabs) overnight at 4°C, followed by incubation with a horseradish peroxidase (HRP)-labeled goat anti-rabbit IgG secondary antibody (1:10,000; cat. no. A16104SAMPLE; Thermo Fisher Scientific, Inc.) for 30 min at room temperature. Immunohistochemical staining was visualized using 3,3′-diaminobenzidine chromogen for 3 min at room temperature. Images were captured using a routine light microscope (magnification: 200×; BX51; Olympus Corporation) and at ≥5 fields in each slide were selected at random.

Experimental groups

Following culture for 24 h, the hypoxic injury model was established using 200 µM cobalt chloride (purity: 97%; Sigma-Aldrich; Merck KGaA), as previously described (21). The NSCs were divided into three groups: i) Normal NSCs group (Control); ii) NSCs hypoxic injury group (Model); and iii) NSCs hypoxic injury + MSCs-EVs group. Following treatment with cobalt chloride for 24 h at 37°C, MSCs-EVs (20 µg/ml) were added to the cells (3×105/ml) for a further 24 h at 37°C. To evaluate the effect of miR-210-3p, an miR-210-3p inhibitor was designed and transfected into NSCs. The NSCs were divided into four groups: i) Control group; ii) hypoxic injury group (Model); iii) hypoxic injury + miR-210-3p NC group (miR-210-3p NC); and iv) hypoxic injury + miR-210-3p inhibitor group (miR-210-3p inhibitor).

Cell transfection

At 70% confluence, NSCs were transfected. The transfection solution consisted of 125 µl Opti-MEM (Gibco, Thermo Fisher Scientific, Inc.), 5 µl Lipofectamine® 3000 (Thermo Fisher Scientific, Inc.) and 12.5 µl RNA inhibitor (RNA inhibitor powder dissolved in diethyl pyrocarbonate; 40 µg/125 µl). The transfection solution was added to the corresponding wells in the 6-well plate for 4 h and the final concentration of miR-210-3p inhibitor was 1 µg/ml. Subsequently, complete medium containing 20% FBS was added to the 6-well plate at 37°C. Then, 48 h later at 37°C, the transfections were verified by reverse transcription-quantitative PCR (RT-qPCR). miR-210-3p inhibitor was synthesized by Anhui General Bioengineering Co., Ltd. The sequences of miR-210-3p inhibitor and NC were UCAGCCGCUGUCACACGCACAG (5′-3′) and UCUACUCUUUCUAGGAGGUUGUGA (5′-3′), respectively.

TUNEL

NSC apoptosis was detected by performing a TUNEL assay (cat no. C1082; Beyotime Institute of Biotechnology) following the manufacturer's protocol. Briefly, terminal deoxynucleotidyl transferase (2 µl) and fluorescent reagent (DAPI, 48 µl) were mixed and applied to the cells at 37°C for 60 min. Following washing by 0.1 M phosphate buffer saline, the slides were covered with anti-fading reagent and observed under a fluorescence microscope (magnification: 200×; BX51; Olympus Corporation) and ≥5 fields in each slide were selected randomly.

Reverse transcription-quantitative PCR

Following treatment, total RNA was extracted from cells using an Ultrapure RNA extraction kit (CoWin Biosciences). The purity of RNA was assessed by measuring the optical density of each sample at a wavelength of 280/260 nm by a spectrophotometer (ShanghaiPuyuan Instrument Co., Ltd.). RNA (1 µg) was reverse transcribed into cDNA using an Avian Myeloblastosis Virus Reverse-Transcriptase kit (cat. no. CW2141S; CoWin Biosciences). The qPCR reaction system included 7 µl RNase-Free dH2O, 1 µl cDNA/DNA, 2 µl primers and 10 µl 2XUltraSYBR Mixture (cat. no. 00081405; CoWin Biosciences). qPCR was performed using the following thermocycling conditions: Predenaturation for 10 min; 40 cycles of denaturation at 95°C for 10 sec, annealing at 58°C for 30 sec and extension at 72°C for 30 sec. The following primers were used for qPCR: U6 forward, 5′-GCTTCGGCAGCACATATACTAAAAT-3′ and reverse, 5′-CGCTTCACGAATTTGCGTGTCAT-3′; and forward, rno-miR-210-3p, 5′-CTGTGCGTGTGACAGCGGCTGA-3′; reverse, 5′-GCACTGCCTGCGGGACATACC−3′. The target gene expression was normalized to U6 using the 2−ΔΔCq method (23).

Western blotting

Following treatment, total protein was extracted from cells using the TriplePrep kit (cat. no. 28-9425-44; ReadyPrep; Cytiva). Total protein was quantified using a bicinchoninic acid protein assay kit (Beyotime Institute of Biotechnology). A total of 25 µg/lane protein was separated via SDS-PAGE (10% gel) and transferred onto nitrocellulose membranes, as previously described (24). The membranes were blocked in 5% skimmed milk at room temperature for 2 h and incubated with the following primary antibodies overnight at 4°C: Rabbit polyclonal anti-Bcl-2 19 kDa interacting protein (BNIP3; 1:1,000; cat. no. ab109362; Abcam), mouse polyclonal anti-apoptosis-inducing factor (AIF; 1:1,000; cat. no. BF0591; Affinity Biosciences) and mouse monoclonal anti-β-actin (1:2,000; cat. no. TA890010; OriGene Technologies, Inc.). The membranes were washed three times with 1X phosphate-buffered saline with 0.05% Tween (PBST) and incubated with secondary antibodies (HRP-labeled goat anti-rabbit IgG; cat. no. 65-6120; Thermo Fisher Scientific, Inc.; HRP-labeled goat anti-mouse IgG; cat. no. 31430; Thermo Fisher Scientific, Inc.) at 4°C for 2 h. Protein bands were visualized using an electrochemiluminescence kit (Thermo Fisher Scientific, Inc.). Protein expression was quantified using the Quantity One software (v4.62; Bio-Rad Laboratories, Inc.) with β-actin as the loading control.

Statistical analysis

Data are presented as the mean ± standard deviation with five experimental repeats in each group. One-way ANOVA followed by the Newman-Keuls post hoc test was used to analyze comparisons between multiple groups. Statistical analyses were performed using SPSS software (version 19.0; IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

Results

Identification of EVs and hippocampal cells

EVs were imaged via transmission electron microscopy (Fig. 1A) and the results indicated that the particle size of EVs was ~150-200 nm (Fig. 1B). The positive rate of nestin, a specific marker of NSCs, in the isolated cells was >98% based on immunohistochemical staining (Fig. 1C), indicating the successful isolation of NSCs.

Figure 1. Identification of EVs and NSCs. (A) Morphology of MSC-EVs observed via transmission electron microscopy (scale bar, 200 nm). (B) Measurement of the particle size. (C) Identification of NSCs isolated from the hippocampus of embryonic Sprague-Dawley rats. Successful isolation of NSCs was indicated by 98% of the cells being nestin-positive (scale bar, 100 µm). EVs, extracellular vesicles; MSC, mesenchymal stem cell; NSCs, neural stemcells.

MSC-EVs reduce hypoxic injury-induced NSC apoptosis, and AIF and BNIP3 expression levels, but promote miR-210-3p expression

Compared with the control group, NSC apoptosis in the model group was significantly higher (Fig. 2). By contrast, NSC apoptosis was significantly reduced in the MSC-EVs group compared with the model group (P<0.05).

Figure 2. MSC-EVs reduce hypoxic injury-induced NSC apoptosis. NSC apoptosis was determined by performing a TUNEL assay (scale bar, 50 µm). *P<0.05 vs. control; #P<0.05 vs. model (n=5 per group). MSC, mesenchymal stem cell; EVs, extracellular vesicles; NSC, neural stem cells.

The expression levels of AIF and BNIP3 in the model group were significantly higher compared with the control group, whereas the expression levels of AIF and BNIP3 in the MSC-EVs group were significantly lower compared with the model group (P<0.05; Fig. 3A).

Figure 3. MSC-EVs reduce AIF and BNIP3 expression levels, but promote miR-210-3p expression levels in hypoxic injury-induced NSCs. (A) AIF, BNIP3 and (B) miR-210-3p expression levels. *P<0.05 vs. control; #P<0.05 vs. model (n=5 per group). MSC, mesenchymal stem cell; EVs, extracellular vesicles; AIF, apoptosis-inducing factor; BNIP3, Bcl-2 19 kDa interacting protein.

Compared with the control group, miR-210-3p expression levels in the model group were significantly higher. In addition, treatment with MSC-EVs further increased miR-210-3p expression compared with the model group (P<0.05; Fig. 3B).

miR-210-3p inhibitor promotes hypoxic injury-induced NSC apoptosis, and AIF and BNIP3 expression levels

Compared with the control group, miR-210-3p expression was significantly reduced in miR-210-3p inhibitor-treated NSCs (P<0.05; Fig. 4A). Additionally, miR-210-3p inhibitor also reduced miR-210-3p expression levels compared with the model group (P<0.05; Fig. 4B). In addition, compared with the model group, miR-210-3p inhibitor increased NSC apoptosis (P<0.05; Fig. 5), and the expression levels of AIF and BNIP3 (P<0.05; Fig. 6).

Figure 4. miR-210-3p inhibitor reduces miR-210-3p expression in NSCs. miR-210-3p expression in (A) normal and (B) hypoxic injured NSCs. *P<0.05 vs. control; #P<0.05 vs. miR-210-3p NC (n=5 per group). miR, microRNA; NSCs, neural stem cells; NC, negative control.

Figure 5. miR-210-3p inhibitor promotes hypoxia injury-induced NSC apoptosis. NSC apoptosis was determined by performing a TUNEL assay (scale bar, 50 µm). *P<0.05 vs. control; #P<0.05 vs. model (n=5 per group). miR, microRNA; NSCs, neural stem cells; NC, negative control.

Figure 6. miR-210-3p inhibitor promotes hypoxia injury-induced AIF and BNIP3 expression in NSCs. miR-210-3p expression levels were determined by western blotting and quantified. *P<0.05 vs. control; #P<0.05 vs. model (n=5 per group). miR, microRNA; AIF, apoptosis-inducing factor; BNIP3, Bcl-2 19 kDa interacting protein.

Discussion

The present study demonstrated that MSC-EVs reduced hypoxia injury-induced NSC apoptosis and promoted miR-210-3p expression. miR-210-3p inhibitor also promoted hypoxia injury-induced NSC apoptosis. Collectively, the results indicated that MSC-EVs possibly reduced apoptosis by modulating the miR-210-3p/AIF/BNIP3 signaling pathway.

Cobalt chloride triggered NSC apoptosis and caused NSC hypoxic injury (21,22). The signaling pathways involved in NSC apoptosis have been investigated; Mfat-1 transgene protects NSCs against cobalt chloride-mediated hypoxic injury by activating Nrf2/ARE signaling pathways (21). The present study demonstrated that MSC-EVs also protected NSCs against cobalt chloride-induced NSC apoptosis. MSCs are beneficial for a variety of diseases including stroke and infection diseases, primarily via self-differentiation and secretory vesicles (25), especially EVs (26,27). EVs reach the injured area more easily than MSCs, as they can pass tissue barriers, such as the blood-spinal cord barrier, with ease (28). In addition, EVs are not susceptible to degradation in comparison with other biological products (29–31); therefore, EVs may serve as therapeutic agents for a range of diseases.

In the present study, EVs were extracted from MSCs, and the transmission electron microscopy and particle size analysis results indicated that the EVs were >100 nm in size, which indicated the concentration and the purity of the extracted exosomes. NSCs were extracted from the hippocampus and cultured in vitro. The results suggested that the positive rate of nestin, a specific protein of neural stem cells, was >98% in the extracted cells, which indicated that the isolation of NSCs from the hippocampus of SD rats was successful. A previous study indicated that exosome therapy can reduce the permeability of the blood-spinal cord barrier following spinal cord injury (32). The results of the present study also suggested that NSC apoptosis was increased in the hypoxic injury model group compared with the control group, but decreased following treatment with MSC-EVs.

The present study indicated that miR-210-3p expression was upregulated under hypoxic conditions compared with control conditions. miR-210-3p is an important post-transcriptional regulator that can inhibit MAX network transcriptional repressor expression, which is closely related to hypoxia (33). miR-210-3p can be activated by hypoxia inducible factor-1α to promote cell survival (34). Reducing miR-210-3p expression antagonizes oxygen-glucose deprivation-induced injury (35). miR-210-3p is also an important regulator of cell apoptosis and proliferation (36). The present study revealed that MSC-EVs further promoted miR-210-3p expression in hypoxia injured NSCs and elevated miR-210-3p expression was beneficial for cell survival. miR-210-3p expression levels were decreased following treatment with miR-210-3p inhibitor in normal NSCs, as well as in hypoxia injured NSCs compared with control NSCs. Moreover, miR-210-3p inhibitor promoted hypoxic injury-induced NSC apoptosis.

The Bcl-2 family is involved in the process of cell injury (37). BNIP3 protein is the most sensitive apoptotic protein to hypoxia (38). BNIP3-induced cell death is characterized by increased plasma membrane permeability and mitochondrial damage in the early stages, but is not accompanied by caspase activation and cytochrome c release (39). AIF is normally located in the mitochondrial membrane gap, but during the stress reaction, AIF is released from mitochondria to cytoplasm and then transferred to nucleus (40). In the nucleus, AIF activates endogenous nucleic acid endonuclease (41). AIF-dependent cell death cannot be reduced by caspase inhibitors, suggesting that AIF does not depend on caspases (42). Under hypoxic conditions, the expression of miR-210-3p in NSCs is upregulated (41). miR-210-3p overexpression can promote NSC survival and proliferation and its mechanism may be related to BNIP3 (43). The present study revealed that the expression levels of BNIP3 and AIF in NSCs cells were decreased following treatment with MSC-EVs, but increased by miR-210-3p inhibitor compared with the model group. miR-210 can target hypoxia-inducible factor 1α to protect renal cells against hypoxia-induced apoptosis (34). miR-210-3p regulates non-small cell lung cancer cell proliferation and apoptosis by targeting paired amphipathic helix protein SIN3 transcription regulator family member A (44). miR-210-3p also targets repulsive guidance molecule A to enhance the angiogenic functions of endothelial progenitor cells under hypoxic conditions (45). However, whether miR-210-3p directly regulates BNIP3 and AIF is not completely understood.

The present study had a number of limitations. First, surface markers, such as cluster of differentiation (CD)9, CD81 and tumor susceptibility 101 were not detectable in the MSC-EVs. In the present study, the sizes of the prepared MSC-EVs were >100 nm, suggesting that these EVs are microvesicles (46), which typically contain CD40 as well as cholesterol, sphingomyelin, and ceramide. Therefore, these surface markers should be detected using sensitive assay methods in subsequent studies. Secondly, the present study suggested that MSC-EVs enhanced miR-210-3p expression, but whether MSC-EVs directly altered miR-210-3p expression was not investigated.

In summary, MSC-EVs prevented NSC hypoxic injury by promoting miR-210-3p expression and reducing apoptosis. Therefore, MSC-EVs may serve as an important treatment strategy for NSC hypoxic injury.

Acknowledgements

Not applicable.

Funding

The present study was supported by the Basic and Application Research in Yunnan Province [grant no. 2017FE468(−251)].

Availability of data and materials

The datasets used and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors' contributions

FL, JZ, RL, YD, LT and YX performed the experiments and analyzed the data. JZ and AC designed the study and wrote the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

All experimental protocols were approved by the Ethics Committee of Kunming Medical University (approval no. KMMU2020180).

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References